Industry Insights

  1. Choosing The Right CDMO Partner For Your Biopharma Molecule 12/1/2025

    Selecting the right CDMO is critical for biopharma success. The ideal partner offers end-to-end capabilities, scientific expertise, quality culture, agility, and transparent collaboration from concept to commercialization.

  2. Oncolytic Viruses Development And cGMP Manufacturing − Experience Matters

    Successfully developing oncolytic virus therapies requires deep manufacturing experience. Understand the strategies, critical cell lines, and production planning necessary to advance these treatments.

  3. Keep Your Eye On The Apple: Apple Makes A Move On The Watch Market—Could Pharma Be Next? 2/18/2015

    CEO of Rolex sounds like a pretty desirable job title and it might have been fun a year ago, when Dufour took the job. Back then, rumors of the Apple Watch were just rumors, and the idea of a tiny computer on the back of your wrist seemed a touch ridiculous.  

  4. Meeting Stability Testing Expectations In A Complex Pharma Landscape

    What was once a check-the-box procedure in standard stability testing now requires a deeper understanding of the molecule, its behavior, and what effect it has on the patient.

  5. Innovating During The COVID-19 Pandemic

    Pharmaceutics International, Inc., (Pii) is a premier CDMO, offering unparalleled scientific insight and depth of product knowledge, while supplying high-quality dosage forms that enhance the lives of patients worldwide. Pii provides customized and flexible solutions across several dosage forms and has experience with a broad range of compounds.

  6. The Promise Of Outcomes-Based Agreements For Cell & Gene Therapies 1/20/2023

    There is a pressing need for stakeholders to find cost-effective ways to help more patients gain access to cell and gene therapies. While many types of innovative payment models exist, outcomes-based agreements — in which manufacturers and payers agree to specific performance and outcome metrics — are emerging as an attractive best practice option for both parties.

  7. How Preclinical And Nonclinical Studies Differ, And Where They Belong 1/11/2022

    Learn when should each term be used, and the appropriate timelines for preclinical and nonclinical studies within a drug development program.

  8. IVDR Survival Guide: Navigating Product Classification & Compliance Expectations 4/17/2023

    Address common questions concerning the IVDR product classification system and how to comply with the new clinical evidence and performance expectations.

  9. Defining Acceptable Impurity Levels For Drug Substances In GLP Toxicology Studies 5/6/2026

    Uncover how aligning impurity profiles between toxicology and clinical drug substance builds translational confidence, supports regulatory readiness, and reduces late‑stage development risk.

  10. xRNA Production: The Economic Case For Continuous Manufacturing 10/31/2025

    See how a continuous manufacturing platform streamlines production to days, uses real-time quality control, and dramatically cuts costs to accelerate access to new therapies.